BioCentury
ARTICLE | Company News

Celgene reports preliminary earnings, adds JAK inhibitor with Impact deal

January 8, 2018 6:59 AM UTC

Celgene Corp. (NASDAQ:CELG) reported preliminary 2017 results and 2018 guidance generally in line with expectations and said it will acquire Impact Biomedicines Inc. (San Diego, Calif.), gaining a late-stage hematology candidate in the process. The financial figures were presented at the JPMorgan Healthcare Conference in San Francisco.

The company reported 4Q17 sales of psoriasis drug Otezla apremilast of $371 million, up 22% from 4Q16 and beating consensus of $340.9 million. The company expects Otezla sales to grow 17% in 2018 vs 2017...